secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001104659-24-041538
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TriSalus reports 77% Q4 revenue growth but warns of late 10-K filing due to stock-comp errors
--------------------------------------------------------------------------------

- Q4 revenue $5.7M (+77% YoY); full year $18.5M (+49% YoY); gross margin improved to 90% and 86%.
- Operating loss Q4 $14.1M, full year $54.2M (incl. $7.9M deSPAC costs); net loss $35.5M and $59.0M.
- Basic/diluted EPS loss Q4 $1.56, full year $6.73 (vs. $75.01/$161.55 in 2022, impacted by deSPAC).
- Will file late 10-K due to stock-based compensation errors; results are unaudited and subject to change.
- CMS granted HCPCS code for TriNav; 510k clearance for TriNav Large and TriGuide; phase 1 trials enrollment completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000110465924041538/0001104659-24-041538-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000110465924041538/tm2410283d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-041538

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer